Alan M Hoberman bought $126k of BIXT
director at BIOXYTRAN, INC. 210,000 shares at an average of $0.60, traded Nov 18, 2025, filed Nov 18, 2025.
Score components
- +15RoleDirector
- +11Trade size$126k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.3%, 3m -30.6%, 6m -50.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001445815-25-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2025 | AGrant or award preferred | +10,417 | $0.49 | $5,052 | 377,619 | Nov 18, 2025 |
| Nov 14, 2025 | AGrant or award preferred | +38,588 | $0.35 | $14k | 416,207 | Nov 18, 2025 |
| Nov 18, 2025 | POpen-market purchase common | +210,000 | $0.60 | $126k | 210,000 | Nov 18, 2025 |
Related signals
Other insiders at BIOXYTRAN, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | BIXTbuy BIOXYTRAN, INC | David Platt CEO | $198k 1,592,921 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.